Cargando…

Evaluation of FLT3-ITD Mutations and MDR1 Gene Expression in AML Patients

BACKGROUND & OBJECTIVE: Acute myeloid leukemia (AML) is a hematopoietic malignancy caused by genetic abnormalities. Currently, molecular and genetic factors are routinely used as diagnostic and prognostic markers. FLT-3 is one of the most known diagnostic factors in AML. MDR1 gene belongs to the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yazdandoust, Ehsan, Sadeghian, Mohammad Hadi, Shams, Seyyede Fatemeh, Ayatollahi, Hossein, Saadatpour, Yasaman, Siyadat, Payam, Sheikhi, Maryam, Afzalaghaee, Monavvar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Iranian Society of Pathology 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745755/ https://www.ncbi.nlm.nih.gov/pubmed/36532642 http://dx.doi.org/10.30699/IJP.2022.543485.2776

Ejemplares similares

Prevalence of MPL (W515K/L) Mutations in Patients with Negative-JAK2 (V617F) Myeloproliferative Neoplasm in North-East of Iran
por: Shams, Seyyede Fatemeh, et al.
Publicado: (2018)

The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran
por: Ayatollahi, Hossein, et al.
Publicado: (2020)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Quantitative assessment of Wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemia
por: Ayatollahi, Hossein, et al.
Publicado: (2017)

Cytogenetic Abnormalities with Interphase FISH Method and Clinical Manifestation in Chronic Lymphocytic Leukemia Patients in North-East of Iran
por: Rahimi, Hossein, et al.
Publicado: (2017)

Evaluation of BAALC gene expression in normal cytogenetic acute myeloid leukemia patients in north-east of Iran
por: Amirpour, Mojgan, et al.
Publicado: (2016)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

KRAS Codon 12 and 13 Mutations in Gastric Cancer in the Northeast Iran
por: Ayatollahi, Hossein, et al.
Publicado: (2018)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
por: Vachhani, Pankit, et al.
Publicado: (2016)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
por: Figueroa, Mary, et al.
Publicado: (2023)

A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment
por: Long, Jun, et al.
Publicado: (2023)

Expression of DR4, DR5, FAS, Caspase-8 and, DDIAS Genes in AML Patients
por: Naghinezhad, Jalal, et al.
Publicado: (2023)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Evaluation of the expression of LC3-II and BECLIN1 genes of autophagy pathway in patients with hematological malignancies
por: Ayatollahi, Hossein, et al.
Publicado: (2023)

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
por: Castaño-Bonilla, Tamara, et al.
Publicado: (2021)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD(+) AML cell growth
por: Weir, Mark C., et al.
Publicado: (2017)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML
por: Wojtuszkiewicz, Anna, et al.
Publicado: (2021)

Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML
por: Schmidt, Franziska, et al.
Publicado: (2022)

Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach
por: Pugliese, Giusj Monia, et al.
Publicado: (2023)

Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation
por: Bogdanov, Konstantin, et al.
Publicado: (2023)

Lack of FLT3-TKD835 gene mutation in toxicity of sulfur mustard in Iranian veterans
por: Ayatollahi, Hossein, et al.
Publicado: (2015)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2019)

Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML
por: Stirewalt, D L, et al.
Publicado: (2014)

Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib
por: Ha, You Na, et al.
Publicado: (2020)

Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT 3‐ITD AML
por: Buelow, Daelynn R., et al.
Publicado: (2019)

Deacetylation of YAP1 Promotes the Resistance to Chemo- and Targeted Therapy in FLT3-ITD(+) AML Cells
por: Feng, Panpan, et al.
Publicado: (2022)

Hsa_circ_0015278 Regulates FLT3-ITD AML Progression via Ferroptosis-Related Genes
por: Jiang, Jiquan, et al.
Publicado: (2022)

P445: A SYSTEMS-BASED APPROACH TO UNVEIL DRUG RESISTANCE IN FLT3-ITD AML
por: Sacco, Francesca, et al.
Publicado: (2023)

Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran
por: Parsa‐kondelaji, Mohammad, et al.
Publicado: (2022)

Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden
por: Minetto, Paola, et al.
Publicado: (2020)

GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations
por: Sportoletti, Paolo, et al.
Publicado: (2019)

Absence of FLT3 mutations in Iranian adult T-cell leukemia/lymphoma patients
por: Ayatollahi, Hossein, et al.
Publicado: (2018)

Mutations in AML with a normal karyotype: NPM1 and FLT3-ITD, ready to use as a key prognosticator?
por: Kim, Hee-Je
Publicado: (2010)

Nuclear membrane-localised NOX4D generates pro-survival ROS in FLT3-ITD-expressing AML
por: Moloney, Jennifer N., et al.
Publicado: (2017)

Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation
por: Tsitsipatis, Dimitrios, et al.
Publicado: (2017)

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
por: Qiao, Xinan, et al.
Publicado: (2021)

Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy
por: Kannan, Sankaranarayan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fj8cbem3qoun5e5ood4j2is8rk